In the Claims:

Claims 1-20 (canceled).

21 (amended). A method ~~of~~ for enhancing an immune response in a mammal comprising administering an antigen and a chemokine to said mammal, wherein said chemokine is MCP-4 or a biologically active fraction of ~~chemokine~~ MCP-4 ~~to said mammal~~.

22 (original). The method of claim 21 wherein said chemokine is recombinant.

23 (original). The method of claim 21 wherein said chemokine is human.

24 (original). The method of claim 21 further comprising administering a substance which allows for the slow release of said chemokine at a delivery site.

25 (canceled).

C1

26 (amended). The method of claim ~~25~~ 21 wherein a fusion protein comprising MCP-4 and antigen is administered to said mammal.

27 (amended). The method of claim ~~25~~ 21 wherein said antigen is a tumor associated antigen.

28 (original). The method of claim 26 wherein said antigen is a tumor associated antigen.

29 (amended). The method of claim ~~25~~ 21 wherein said antigen is a bacterial, viral or fungal antigen.

30 (original). The method of claim 26 wherein said antigen is a bacterial, viral or fungal antigen.

31 (amended). The method of claim ~~25~~ 21 wherein said tumor associated antigen is selected from the group consisting of Melan-A, tyrosinase, p97, β-HCG, GaINAc., MAGE-1, MAGE-2, MAGE-3, MAGE-4, MAGE-12, MART-1, MUC1, MUC2, MUC3, MUC4, MUC18, CEA, DDC, melanoma antigen gp75, Hker 8, high molecular weight melanoma antigen, K19, Tyrl and Tyr2, members of the pMel 17 gene family, c-Met, PSA, PSM, α-fetoprotein, thyroperoxidase, gp 100, p53 and telomerase.

32 (original). The method of claim 26 wherein said tumor associated antigen is selected from the group consisting of Melan-A, tyrosinase, p97, β-HCG, GaINAc., MAGE-1, MAGE-2, MAGE-3, MAGE-4, MAGE-12, MART-1, MUC1, MUC2, MUC3, MUC4, MUC18, CEA, DDC, melanoma antigen gp75, Hker 8, high molecular weight melanoma antigen, K19, Tyrl and Tyr2, members of the pMel 17 gene family, c-Met, PSA, PSM, α-fetoprotein, thyroperoxidase, gp 100, p53 and telomerase.

33 (amended). The method of claim ~~25~~ 21 further comprising administering a combination of GM-CSF and IL-4.

34 (original). The method of claim 26 further comprising administering a combination of GM-CSF and IL4.

35 (amended). The method of claim 21 further comprising administering ~~an~~ a dendritic cell activating agent with said chemokine.

36 (original). The method of claim 21 wherein said chemokine is administered intradermally, intramuscularly, subcutaneously, topically, or in the form of a vector.

Claims 37-68 (canceled)

69 (original). The method of claim 35 wherein the activating agent is a nucleic acid containing an unmethylated CpG motif.